Overview of positron emission tomography in functional imaging of the lungs for diffuse lung diseases

Positron emission tomography (PET) is a quantitative molecular imaging modality increasingly used to study pulmonary disease processes and drug effects on those processes. The wide range of drugs and other entities that can be radiolabeled to study molecularly targeted processes is a major strength...

Full description

Saved in:
Bibliographic Details
Published in:British journal of radiology 2022-04, Vol.95 (1132), p.20210824-20210824
Main Authors: Gulhane, Avanti V, Chen, Delphine L
Format: Article
Language:English
Subjects:
Functional imaging of the lung special feature: Review
Humans
Lung - diagnostic imaging
Lung Diseases - diagnostic imaging
Molecular Imaging
Positron-Emission Tomography - methods
Radiopharmaceuticals
Tomography, X-Ray Computed
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Positron emission tomography (PET) is a quantitative molecular imaging modality increasingly used to study pulmonary disease processes and drug effects on those processes. The wide range of drugs and other entities that can be radiolabeled to study molecularly targeted processes is a major strength of PET, thus providing a noninvasive approach for obtaining molecular phenotyping information. The use of PET to monitor disease progression and treatment outcomes in DLD has been limited in clinical practice, with most of such applications occurring in the context of research investigations under clinical trials. Given the high costs and failure rates for lung drug development efforts, molecular imaging lung biomarkers are needed not only to aid these efforts but also to improve clinical characterization of these diseases beyond canonical anatomic classifications based on computed tomography. The purpose of this review article is to provide an overview of PET applications in characterizing lung disease, focusing on novel tracers that are in clinical development for DLD molecular phenotyping, and briefly address considerations for accurately quantifying lung PET signals.
ISSN:0007-1285
1748-880X
DOI:10.1259/bjr.20210824